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Abstract. Alzheimer’s disease (AD) is the most prevalent form of dementia and the number of cases is expected to increase
exponentially worldwide. Three highly penetrant genes (AβPP, PSEN1, and PSEN2) explain only a small number of AD cases
with a Mendelian transmission pattern. Many genes have been analyzed for the association with non-Mendelian AD, but the only
consistently replicated finding is APOE. At present, possibilities for prevention, early detection, and treatment of the disease are
limited. Predictive and diagnostic genetic testing is available only in Mendelian forms of AD. Currently, APOE genotyping is not
considered clinically useful for screening, presymptomatic testing, or clinical diagnosis of non-Mendelian AD. However, clinical
management of the disease is expected to benefit from the rapid pace of discoveries in the genomics of AD. Following a recently
developed framework for the continuum of translation research that is needed to move genetic discoveries to health applications,
this paper reviews recent genetic discoveries as well as translational research on genomic applications in the prevention, early
detection, and treatment of AD. The four phases of translation research include: 1) translation of basic genomics research into a
potential health care application; 2) evaluation of the application for the development of evidence-based guidelines; 3) evaluation
of the implementation and use of the application in health care practice; and 4) evaluation of the achieved population health
impact. Most research on genome-based applications in AD is still in the first phase of the translational research framework,
which means that further research is still needed before their implementation can be considered.
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INTRODUCTION
Alzheimer’s disease (AD) is the most common cause
of dementia and the most frequent neurodegenerative
disorder associated with aging. Currently, 5.3 million
Americans are diagnosed with AD, accounting for 60–
80% of all dementia cases in US [1]. As a result of
the aging population, the number of patients with AD
is expected to increase exponentially [2].
Rapid advances in genomics of AD have fueled enor-
mous expectations about future use of susceptibility
variants for prevention, diagnosis, and treatment of the
disease [3]. Evidence for a strong genetic contribution
has consistently been documented in twin and family-
based linkage studies. Heritability estimates from a
large twin study suggest that genetic variations may ac-
count for about 58% to 80% of AD risk and a few vari-
ants for monogenic subtypes have been identified [4].
Large numbers of susceptibility genetic variants are in-
vestigated for their putative association with AD and a
plethora of translational research exists. With respect
to AD, genome-based tests potentially can improve the
diagnosis, prognosis or prediction, and treatment of
AD.
A clinical diagnosis of AD is based on clinical ex-
amination and neuropsychological testing, and mainly
involves the exclusion of other causes of dementia. Fa-
cilitated by the neuropsychological and structural neu-
roimaging advances, the accuracy of the clinical di-
agnosis has increased to 80–90% [5], but a definite
diagnosis still awaits neuropathological confirmation.
Genome-based tests and improved imaging are envi-
sioned to improve the differential diagnosis and to pro-
vide a basis for disease subtypes characterization.
Predicting the development and prognosis of AD is
difficult because the disease has a complex etiology
with genetic and environmental factors playing an in-
tricate role. The lifetime risk in individuals who have
a first-degree relative with late onset AD was evaluated
to be about 2 to 4 times higher than in individuals with-
out affected first-degree relatives [6]. The incidence of
AD increases from 1.2 per 1000 person years in the
65–69 years age group to 53.5 per 1000 person years
in the older than 90-year age group [7]. Advanced age
and positive family history are the only risk factors
which have become firmly established [8,9]. There al-
so seems to be a gender distribution of risks for AD,
CA Rotterdam, The Netherlands. Tel.: +31 10 704 4232; Fax: +31
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with a higher prevalence of dementia in women than in
men, predominantly after age 75 [2,8]. Genetic testing
is investigated for identifying at risk individuals be-
fore the clinical onset of disease, given that preventive
measures will be proven to be efficacious.
Currently available treatment is symptomatic and
cannot delay progression of the neurodegenerative pro-
cess. Cholinesterase inhibitors (donezepil, rivastig-
mine, and galantamine) and the NMDA partial antago-
nist memantine are used for the management of the cog-
nitive symptoms, but these agents are moderately ef-
fective in 30% to 40% of mild-to-moderate AD patients
with side-effects, intolerance, and noncompliance in>
60% of treated individuals [10–12]. Additionally, neu-
roleptic and antidepressant medication is often used for
associated psychiatric symptoms. Several Phase I, II,
and III clinical trials that investigate new therapeutic
strategies, such as γ-secretase modulators, amyloid-β
aggregation inhibitors, passive and active vaccination,
and light therapy, have shown improvement of cog-
nitive function [13,14]. It is envisioned that genome-
based tests can identify subgroups of patients in which
the specific therapies may be effective.
In the past few years, there has been increasing in-
terest in investigating the potential clinical and pub-
lic health applications of genetic tests in AD. This re-
view summarizes the recent advances in translational
research, following the framework for the continuum
of translation research described by Khoury and col-
leagues [15]. This framework specifies four stages of
scientific evidence in translation research and therewith
identifies the most likely applications of genetic testing
in the clinical management of AD in the near future.
The paper starts with a review of genetic discoveries in
AD and presents the future applications against the cur-
rent place of genetic testing in the prediction, diagnosis
and treatment of AD.
To identify applicable articles, we performed a
search for publications in MEDLINE from January
2006, and in the lists of references from retrieved ar-
ticles. We used a combination of the following key-
words: “Alzheimer”, “genetic”, “genomic”, “screen-
ing”, “prognosis”, “prediction”, “diagnosis”, “thera-
py”, “treatment”, “intervention”, “risk”, “advances”,
“trend”, “innovation”, “progress”, “emerging”, “devel-
opment”, “insight”, “utility”, “guideline”, “decision
making”, “state medicine”, “translational medicine”,
and “translational research”. We considered for inclu-
sion in our analysis: editorials, reviews, meta-analyses,
original scientific papers published in peer-review jour-
nals, and evidence-based practice guidelines. A draft
report was written and discussed in an expert meeting
to verify and complete all retrieved information.
R. Mihaescu et al. / Translational Genomics of Alzheimer’s Disease 969
Table 1
Mutations in families with autosomal dominant Alzheimer’s disease (AD)
Gene Penetrance Chromosome Frequency of mu-
tation in families
with autosomal
dominant AD
Number of
pathogenic
mutations∗
Age of onset References
Established Factors
PSEN1 Complete 14q24.3 20–70% 177 28–50 years [16, 81]
AβPP Complete 21q21 10–15% 32 45–65 years [16, 81]
PSEN2 Incomplete 1q31-q42 Rare 14 40–85 years [16, 81]
Investigated Factors
PGRN (progranulin gene) Incomplete 17q21-22 Rare 68 35–89 years [82]
MAPT (Tau gene) Complete 17q21.1 Rare 44 40–60 years [83]
∗From Alzheimer’s Disease & Frontotemporal Dementia Database website [21].
GENETICS OF AD
From a genetic perspective, a distinction is made be-
tween Mendelian and non-Mendelian forms of AD. On-
ly a small percentage of cases present with a Mendelian
transmission pattern and a disease onset generally be-
fore 60–65 years (early-onset Alzheimer’s disease,
EOAD). Most AD cases present with a non-Mendelian
transmission pattern and have an older age at diagno-
sis (late-onset Alzheimer’s disease, LOAD). LOAD is
mostly sporadic, but in approximately 25% of cases
with LOAD, another affected relative can be identi-
fied [16]. Non-Mendelian AD is considered to be eti-
ologically more complex than Mendelian AD and may
involve multiple susceptibility genes that interact with
other genes and with environmental risk factors. The
distinction between EOAD and LOAD, however, is ar-
bitrary, since clinical and pathological features are sim-
ilar in both groups, and it is no longer used by most
experts.
So far, three causal genes have been identified in a
few hundreds of families in the world, which togeth-
er account for a small percentage of Mendelian AD:
amyloid-β protein precursor (AβPP) gene on chromo-
some 21 [17], presenilin 1 (PSEN1) gene on chromo-
some 14 [18], and presenilin 2 (PSEN2) gene on chro-
mosome 1 (Table 1) [19,20]. These genes are not found
in non-Mendelian AD [21]. Almost all carriers of a
mutation in the AβPP or PSEN1 genes will eventually
develop the disease, but the mutations in the PSEN2
gene are not completely penetrant with carriers show-
ing large variations in the age of onset [22].
To date, the most commonly replicated genetic risk
factor for sporadic AD is the gene coding for the
apolipoprotein E, located on chromosome 19 [23].
Three common alleles of the APOE gene have been
identified: ε2, ε3, and ε4. The APOE ε4 allele is more
frequent in patients with non-Mendelian AD, compared
to controls [24]. About half of the patients with spo-
radic AD carry an APOE ε4 allele [25]. The APOE
gene is moderately penetrant, with each additional copy
of the ε4 allele increasing the risk of AD (OR = 2 to
8 depending on the population studied) and correlating
with a slightly younger age at dementia onset [25,26].
In individuals with a positive family history, the risk
of AD for carriers of a single APOE ε4 allele was es-
timated to be 3 times higher compared to other APOE
genotypes, and carrying two ε4 alleles was associated
with a 15 to 30 fold increase in risk of AD [27]. The
association between APOE ε4 allele and AD is stronger
among women than among men [25]. Although the
association between APOE ε4 and the risk of AD is
evident in all ages between 40 and 90 years, it becomes
weaker after the age of 70 years [25].
In the past decades, numerous studies have tried
to identify susceptibility genes for AD investigat-
ing hundreds of putative risk alleles in more than
500 genes [28]. The genome-wide association studies
(GWAS) performed in the field of AD research con-
firmed the APOE locus as the major susceptibility gene
for non-Mendelian AD [29]. All other newly identified
susceptibility genes each confer only a small increase
in disease risk (Table 2) [30], and altogether explain
only a small part of the genetic risk of AD. Based on ev-
idence from meta-analyses of genetic association stud-
ies, several genes are considered candidates for associ-
ation with AD risk (Table 3) [28]. To be noted, however,
the very modest relative risks which confirm the expec-
tations that probably no other single gene will account
for a high percentage of non-Mendelian AD. Improve-
ments in the characterization of patients, e.g., by further
distinction of subtypes, may still uncover other strong
genetic variants, and strong effects might be expected
from gene-gene and gene-environment interactions.
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Table 3
Top ten non-Mendelian Alzheimer’s disease genes from meta-analyses of four or more independent
samples [28]
Gene SNP Population Associated Effect size† Total size (cases
allele∗ & controls)
APOE ApoE Caucasian ApoE ε4 vs. ε3 3.81 (3.38–4.29) 7812
(ε2/3/4) ε2/3/4 ApoE ε2 vs. ε3 0.56 (0.40–0.79)
CLU rs11136000 All T 0.85 (0.82–0.89) 26246
PICALM rs541458 All C 0.87 (0.83–0.91) 21915
TNK1 rs1554948 All A 0.86 (0.80–0.93) 5727
ACE rs1800764 Caucasian C 0.79 (0.68–0.92) 1565
TFAM rs2306604 All G 0.82 (0.72–0.94) 1851
CST3 rs1064039 Caucasian A 1.16 (1.00–1.33) 3014
IL1B rs1143634 Caucasian T 1.18 (1.04–1.35) 2255
CR1 rs6656401 Caucasian A 1.19 (1.09–1.28) 17181
hCG2039140 rs1903908 Caucasian T 1.23 (1.06–1.44) 2865
∗When effect size is < 1.00 allele is protective.
†Effect size expressed as per allele odds ratios.
CURRENT APPLICATIONS OF GENETIC
TESTING
A number of evidence-based guidelines of genet-
ic testing in AD are currently available [31–33]. At
present, genetic testing is mainly used for monogenic
forms of AD, solely in presymptomatic and diagnos-
tic settings and so far has no application in therapeutic
strategies.
Presymptomatic testing
Presymptomatic testing for mutations in AβPP,
PSEN1, and PSEN2 genes can be performed in the pres-
ence of a positive family history of autosomal dominant
inheritance and if a mutation is documented in an affect-
ed relative [33,34]. Criteria for the definition of a posi-
tive family history are, however, unclear. Prenatal diag-
nosis and preimplantation genetic diagnosis (PGD) are
two options available for families with autosomal dom-
inant disease with a documented causal mutation [35].
Prenatal diagnosis establishes the carrier status in an
offspring during the pregnancy, whereas PGD consist
of testing the embryos before the pregnancy is estab-
lished [36,37]. Presymptomatic testing in children of
adults with known mutations is not encouraged because
of ethical and psychological concerns [31].
Presymptomatic genetic testing is available only for
monogenic forms of disease. APOE genotyping for
presymptomatic testing of non-Mendelian AD is not
recommended, because the sensitivity and specificity
of APOE testing with respect to detection of individuals
at risk for AD are too low, i.e., not all patients with AD
carry the ε4 allele and not all ε4 carriers will develop
AD [33,34]. APOE genotyping is discouraged because
of the presumed psychological harm, the impact on the
relatives of a patient carrying two APOE ε4 alleles, and
the lack of specific treatment for individuals at genet-
ic risk [38]. However, despite the scarce evidence to
support the role of predictive genetic testing for AD,
several commercial companies already offer direct-to-
consumer testing to predict risk of AD, basing their pre-
diction on testing the APOE related single-nucleotide
polymorphisms [39]. The Risk Evaluation and Educa-
tion for Alzheimer’s Disease (REVEAL) study evalu-
ated the 1 year effect of APOE genotype disclosure to
adults with a parent with AD and found no difference
between levels of anxiety and depression between in-
dividuals who received and those who did not receive
APOE genotype disclosure [40]. However, effects may
differ with longer follow-up and outside research set-
tings, when it is unknown if people receive information
about the limitations of single genetic tests [41].
Diagnosis
Differential diagnosis in patients with clinical di-
agnosis of AD and a family pattern of autosomal
dominant inheritance may involve testing for known
pathogenic mutations [33]. Testing for common muta-
tions in AβPP, PSEN1, and PSEN2 genes can also be
considered in cases presenting with clinical symptoms
of dementia at younger age but without a positive fami-
ly history [42]. Genetic testing is also done postmortem
in families with autosomal dominant disease to assist
the future diagnosis of at risk relatives [33].
APOE testing is considered potentially useful to
identify the cause of a dementia syndrome, i.e., to test
whether the dementia is caused by AD. However, ge-
netic testing for APOE gene is not part of the routine
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Table 4
Developments in genomics research in Alzheimer’s disease (AD) according to the framework for translation research [15]
Discovery to candidate health
application
Health application to evidence-
based practice guidelines
Practice guide-
lines to health
practice
Practice
to population
health impact
Presymptomatic
Testing
Prediction of AD and predementia
using prediction models with ge-
netic and non-genetic risk factors
APOE testing to identify high-risk
groups: clinical validity, attitudes,
behavioral change and psycholog-
ical impact
None None
Prevention None None None None
Diagnosis Clinical validity of APOE testing
for more accurate dementia diag-
nosis in sporadic cases
None None None
Therapy Pharmacogenetics:
– Interaction between genetic fac-
tors and treatment
– Genetic profiles for prediction of
treatment results
None None None
laboratory investigations during the differential diag-
nosis of dementia, because the positive and negative
predictive values of the test are too low [32].
TRANSLATIONAL GENOMIC RESEARCH IN
AD
Although only limited opportunities are available for
genetic testing in the prevention, early detection, and
treatment of AD, there is extensive ongoing research
aiming at integrating the genetic discoveries into clin-
ically useful tools. It has been acknowledged that sev-
eral research stages are required before genetic discov-
eries can be implemented into health care. Khoury and
colleagues have described a framework for the contin-
uum of translational research that is required to move
genomics research findings to clinical and public health
applications that benefit population health [15]. The
four phases of translation research include: 1) transla-
tion of basic genomics research into a potential health
care application; 2) evaluation of the application for the
development of evidence-based guidelines; 3) evalua-
tion of the implementation and use of the application in
health care practice; and 4) evaluation of the achieved
population health impact [15]. Thus, the framework
indicates how close a genetic application is to clinical
and public health practice. The major developments in
genomics of AD, for each phase of translation research,
are summarized in Table 4.
Discovery to candidate health application
Examples of relevant candidate health applications
in AD research are the development of single gene tests
and construction of genomic profiles, to be used for
prediction, screening, diagnosis, and targeted treatment
of the disease. The aim of phase one translation re-
search is to determine the sensitivity, specificity, and
positive predictive value of the genetic tests for these
applications [15].
Genome-based prediction of AD
Apart from testing for monogenic subtypes in high
risk patients, where clinical utility is clear, genetic pre-
diction of complex diseases consists of testing multiple
genes, or multiple genes added to traditional risk fac-
tors. A recent study suggested that polymorphisms in
10 genes (APOE, LDLr, CST3, CTSD, TNF, BACE1,
MAPT, STH, eNOS, TFCP2) may help to distinguish
among three clusters of patients with non-Mendelian
AD: a young group of 60–69 years with a risk allele
on genes related to plaque deposition, a second group
of 70–80 years and risk alleles on genes related to neu-
rofibrillary tangles formation, and a third group of <
65 and 70–85 years and risk alleles on inflammation
genes [43]. Other case-control studies have identified
AD-risk profiles based on clusters of genes related to
cholesterol or inflammation with promising predictive
values [43–47]. Further research is needed to validate
whether these genomic profiles can prospectively iden-
tify individuals at risk to develop AD.
To date, only a few studies have included multiple
variants in AD prediction models, but most have con-
sidered only the APOE genotype among other non-
genetic risk predictors. An example of AD risk predic-
tion model that incorporates APOE status is the devel-
opment of risk curves specific to ethnicity, age, gender,
and APOE genotype from the REVEAL study [48].
Motivated by an increased risk for AD in African Amer-
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icans, and after a careful evaluation of ethical princi-
ples, separate risk curves were constructed for white
and African American first-degree relatives of patients
with AD. Cumulative risk curves stratified by ethnici-
ty and genotype showed that risk was lower than 10%
until age 60, afterwards the risk increased for all ethnic
groups but more steeply with African American ethnici-
ty and APOE ε4 genotype [48]. Moreover, observation-
al studies and randomized control trials have shown that
environmental risk factors such as physical inactivity,
dietary fat intake, alcohol drinking, smoking at midlife,
diabetes, and traumatic brain injury were stronger as-
sociated with dementia and AD among APOE ε4 carri-
ers than in non-carriers, indicating an interaction effect
between these two factors [49,50].
Finally, prospective cohort studies indicated that ge-
netic testing for APOE could be useful in selecting pa-
tients at risk of progression from mild cognitive impair-
ment (MCI) to dementia, but further studies are needed
to demonstrate the beneficial impact of this risk infor-
mation [35,51]. For example, a longitudinal study that
uncovered an increased association between APOE ε4
carrier status and conversion to AD in older individuals
with MCI failed to prove APOE ε4 carrier status useful
to predict conversion of MCI to AD [52].
Genetic testing to improve diagnostic accuracy
Genetic tests may add to other laboratory tests com-
monly used to identify whether the dementia is due to
AD. A large study that assessed the clinical validity of
adding the APOE status to the clinical diagnosis showed
that the area under the ROC curve (AUC) increased
from 0.84 based on clinical factors to 0.87 when APOE
was added to the clinical factors [5]. This difference
in AUCs was statistically significant, suggesting that
genotyping for APOE provides additional information
in patients who meet the clinical criteria for AD.
Genetic risk factors are also used in research settings
to uncover the biological markers related to sub-clinical
stages of the disease. The correlation between APOE
genotypes and different endophenotypes were investi-
gated by a number of prospective clinical multicentre
trials which aimed to find new variables for detection
of preclinical AD [51,53,54]. These studies suggest-
ed that APOE ε4 genotype correlates most strongly
with the cerebrospinal fluid levels of amyloid-β protein
42 amino acid form, cerebral glucose metabolism, and
quantitative EEG (i.e., decreased alpha rhythm during
rest and dysfunction of deep brain structures during hy-
perventilation). Another example comes from a study
that tested 500 transcripts of AD associated genes for
their use in prediction of incipient AD [55]. In two
datasets of around 30 postmortem brain samples each
from the hippocampus (i.e., Blalock dataset) and the
entorhinal cortex (i.e., Dunckley dataset), increased or
decreased amounts of specific gene products were con-
sistently found in individuals with incipient AD (i.e.,
Braak stages III-IV), indicating that testing for these
genes may be useful in identifying individuals at sub-
clinical stages of the disease [55].
Genome-based prediction of treatment response
Genetic testing can improve the treatment by in-
creasing drug efficacy and safety. Also, genetic tests
can be used to select patients for therapies that target
specific genes or gene products. Several recent studies
of pharmacogenomic research in AD have suggested
that therapeutic response to cholinergic agents might
depend on genotype at APOE, PSEN1, PSEN2, and
CYP2D6 genes, however, results are conflicting [12,
51,56]. For example, some studies reported worse re-
sponse to cholinergic enhancers in APOE ε4 carriers,
but others found no association between the APOE
genotype and response to galantamine [51]. Howev-
er, recent studies showed that APOE genotype is cor-
related to clinical phenotype in terms of cognitive im-
pairment in AD, supporting the existence of differ-
ent subtypes of AD that may influence therapeutic re-
sponse [57–59]. In addition, studies of neurotransmit-
ter genes suggest that neuroleptic and antidepressant
medication may be effective in selected groups of pa-
tients based on their genetic profile [51,60]. For exam-
ple, variants in dopamine 2 and serotonin 2A receptors
have been associated with early response to neurolep-
tics and response to clozapine and risperidone, respec-
tively [60].
Clinical trials of new therapeutic strategies may al-
so benefit from genetic testing. Combining APOE sta-
tus with information from neuroimaging studies has
proven to be a useful strategy for early detection of
subtle brain abnormalities that may precede more ad-
vanced stages of AD (i.e., 4% left posterior cingulat-
ed metabolic decline at 2 years follow-up in APOE
ε4 carriers), suggesting that a combination of genetic
variants and cerebral metabolic rates may be useful in
monitoring experimental treatment response [61].
Apart from modifying the efficacy of available drugs,
the discovery of new variants has also led to the devel-
opment of drug treatments that target specific genes.
For example, risk profile carrier status on genes relat-
ed to inflammation or estrogen metabolism may de-
termine the response to therapeutic strategies in these
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pathways. Studies of genetic profiles of immune re-
lated gene polymorphisms indicated that only patients
with early onset AD and fast clinical deterioration show
definite pro-inflammatory genetic profiles, suggesting
that anti-inflammatory drugs may be especially useful
in these patients [62]. Considering the role of estrogens
in the pathology of AD and the differences in vulnera-
bility to cognitive dysfunctions in women, other groups
have looked at the genetic variability in estrogen re-
ceptors [63]. Polymorphisms in estrogen receptors α
and β were associated with an increased risk of AD,
with a recent study showing that estrogen receptor α
splice variants expression pattern changes with aging
and in AD [63,64]. Observational studies and meta-
analyses suggested a neuroprotective effect of the hor-
mone replacement therapy [63], but this failed to be
confirmed by a large RCT trial that was stopped due
to an increased risk for breast cancer and stroke in the
treatment groups [65].
Finally, Phase I and II clinical trials evaluate a large
number of disease modifying drugs, many of them tar-
geting the amyloid-β pathway [66,67]. Most of these
drug trials also evaluate genetic markers among other
baseline characteristics of the subjects enrolled in the
study, and this may provide further insight on genet-
ic variation associated with treatment response. For
example, a Phase II clinical trial of the PPARγ ag-
onist rosiglitazone showed improvement in cognitive
functioning in treated patients compared to placebo,
but only if they were non-carriers of the APOE ε4
allele [68]. Similar results were reported in trials of
the anti-amyloid-β monoclonal antibody bapineuzum-
ab [69] and the ketogenic compound AC-1202 [70], in-
dicating that APOE genotyping is relevant in pharma-
cogenomic research. Conversely, studies which aim to
identify risk profiles (i.e., inflammatory profiles com-
prised of alleles of pro/anti-inflammatory cytokines)
will potentially allow both the early identification of
individuals susceptible of developing AD and the pos-
sible design or utilization of a drug with enhanced safe-
ty [71].
Health application to evidence-based practice
guidelines
The second phase of translation research starts after
there is convincing evidence on genetic tests perfor-
mance. In this phase, the clinical validity and utility
of genetic tests are measured in the population settings
for which the tests are primarily intended. Results from
the second phase of translation research should lead to
evidence based reviews and guidelines for clinical and
public health practice [15]. Although there is increas-
ing use of genetic testing for clinical and scientific use,
current practices vary across memory research centers.
To date, all guidelines recommend against APOE
genotype testing for screening, early detection, or diag-
nosis of AD due to a low sensitivity,specificity, and pos-
itive predictive value and the possible negative health
outcomes associated with testing. However, recent data
from the REVEAL study showed that APOE genotype
disclosure in adult children of patients with AD has
no negative short-term psychological impact in carriers
and non-carriers of the risk allele [40]. This is in line
with the findings reported by a systematic review of
psychological and behavioral consequences of genetic
testing [72].
Assessment of social and behavioral issues linked to
genetic tests is an important aspect of second phase of
translation research. The REVEAL study showed that
women, highly educated persons, and persons below
60 seemed to be more interested in genetic testing for
AD, and that primary motivation for undertaking the
tests were advance planning and emotional coping with
the threat of disease [73]. Health behavior analyses in
the REVEAL study suggested that disclosing increased
risk status can motivate adoption of activities believed
to lower the risk of AD, such as dietary and lifestyle
changes [73].
Practice guidelines to health practice and practice to
population health impact
The third phase of translation research addresses
the spreading and integration of knowledge gained
through the second phase research. It involves both pub-
lic and professional/private participation for adoption
of proved genomic application [15]. The fourth phase
of translation research focuses on clinical and public
health outcomes of adopted guidelines and includes
measures of disease incidence, quality-of-life indica-
tors, clinical decision modeling, and cost-effectiveness
analysis, among others [15].
Currently, there is limited data available on the im-
plementation of the novel genomic applications into
health practice. As most of translation research in AD
is still in the first phase, studies that assess the popu-
lation health impact are limited to Mendelian AD, if
available at all.
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CONCLUSION
AD shows typical characteristics of a Mendelian dis-
order in a small number of cases, however, in most
cases, AD is a complex disorder in which gene-gene
and gene-environment interaction play a major role. To
date, diagnosis is usually made after the disease pro-
cesses are likely to be irreversible and therapeutics of
AD includes only symptomatic drugs that cannot halt
the disease progress. Much hope is placed on the ge-
nomic discoveries in AD which are expected to im-
prove presymptomatic testing, diagnosis, and treatment
of AD. In this review we have summarized the current
use of genomic information in the clinical management
of AD and described the most likely future applica-
tions in the context of the four translational research
phases in genomics of AD. Relevant literature was re-
trieved from a MEDLINE search, and included edito-
rials, reviews, meta-analyses, original scientific papers
published in peer-review journals, and evidence-based
practice guidelines subsequently discussed in an expert
meeting.
Many genes are analyzed for the association with
sporadic AD, but the only consistently replicated find-
ing is the APOE gene, which is found in almost half
of the sporadic cases. Given the small predictive value
of genetic testing for APOE, it is not considered clin-
ically useful for screening, presymptomatic testing, or
clinical diagnosis. All genes identified through GWAS
have small effects on disease risk and none of them can
be used individually for screening or predictive testing.
Instead, testing at multiple loci is evaluated for its role
in identifying people at higher risk of developing AD.
Whether genetic profiling can be useful depends on
many factors that influence its clinical validity and util-
ity. It has been previously shown that the discrimi-
native accuracy of genetic profiling depends upon the
heritability and prevalence of the disease, as well as
on the genotype frequency [74]. Besides, disease risk
prediction based on multiple factors, each with weak
effects, yields a continuum of risks, with only a small
proportion of people at high risk, and the majority at
a slightly higher or lower disease risk than the aver-
age disease risk in the population [75]. Gene-gene and
gene-environment interactions may further influence
the disease risk.
Moreover, none of the investigated new preventive
measures has proven effective, as reflected by incon-
sistencies in reports from studies of anti-inflammatory
agents, estrogens, nerve growth factors, ginkgo biloba,
statins, amyloid vaccination, or antioxidants in preven-
tion of AD [33,76,77]. Experts are reluctant on the
desirability and usefulness of predictive genetic test-
ing for susceptibility to AD as long as there are no
effective opportunities for prevention [78]. While the
availability of interventions may be a criterion for the
clinical implementation of tests, this does not hold for
commercial applications. APOE genotyping is already
commercially available in the genome scans offered
by companies like Navigenics and deCODEMe [39].
The question remains whether healthcare should step
into direct to consumer genetic testing and offer ge-
netic testing with better counseling, or if it should re-
frain from it to make clear that these tests are relatively
uninformative.
Treatment is similar for autosomal dominant or spo-
radic AD. Several genes are good candidates expect-
ed to play a role in variability of drug disposition and
pharmacodynamics in AD, but the place of genetic pro-
filing for clinical use is not determined yet. At present,
therapeutic interventions for AD do not take into ac-
count the underlying genetic risk of the patient. Prob-
ably, the most important gain from genetic discoveries
is the identification of biological pathways involved,
which may improve our understanding of the patholog-
ical mechanism underlying AD. This in turn may lead
to a better definition of disease subtypes and provide
us with new targets for drug activity and more effective
treatments, by targeting individuals who benefit most.
The limitations of our present understanding and
knowledge of the disease, and therefore in prevention
and treatment of at risk individuals, raise important eth-
ical concerns regarding current applications of predic-
tive genetic testing. As a result, genetic research and the
potential implementation of genetic testing into clini-
cal and public health practice are carefully monitored
through the evaluation of the ethical, legal, and so-
cial issues [79,80]. The European Dementia Consensus
Network (EDCON) has developed a consensus state-
ment on ethics of dementia research [79]. Summariz-
ing the report, top priority was given to the following
issues: informed consent, disclosure of diagnosis of
dementia, protection of patients, privacy of genetic da-
ta, and protection of relatives. Furthermore, it became
evident that the most important step for further research
is to promote a concerted involvement of researchers,
patients’ organizations, funding bodies, and politicians
in defining research priorities.
In the future, applications of genetic testing in AD
may play a role in the identification of presymptomatic
individuals at high risk of developing the disease, the
inclusion of genomic profiling into the armamentarium
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for early diagnosis of AD, selection of effective inter-
ventions, and drug dosage adjustment as predicted by
the genetic profiles. Genetic screening and predictive
testing for AD will only become useful if genetic tests
have sufficient predictive value and effective preventive
measures will become available. Genetic variants with
strong effects, both rare and common, either on their
own or in interaction with other genes or environmen-
tal factors, might further improve the prediction of AD
in asymptomatic individuals, yet most still need to be
discovered. However, most research on genome-based
applications in AD is still in the first phase of the trans-
lational research framework, which means that massive
research is still needed before their implementation can
be considered.
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